Side effects can vary greatly.

In one case, a male patient sued a pharmacy on the basis that he had not been properly counseled about priapism when he stuffed his trazodone prescription. He woke up with a persistent erection and sought medical attention 30 hours later. The patient had emergency surgery and was left impotent permanently. The pharmacy was found to become 51 percent negligent, and the plaintiff was awarded $357,000 in damages. READ ON >> Hair Growth Not every unexpected side effect is scary, as some patients welcome effects such as for example hair growth. For instance, finasteride was first introduced to treat non-cancerous enlargement of the prostate gland, but now, additionally it is used to take care of female hair reduction in conjunction with an oral contraceptive because of a known birth defect potential.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, ‘The termination of our contract with sanofi-aventis U.S. Was expected in light of last week’s announcement. Our clinical development efforts will now be centered on the following late-stage substances: in oncology, Keryx, our licensee and partner in North America, has initiated a Stage 3 trial in multiple myeloma with perifosine just, our oral PI3K/Akt inhibitor compound. We are also currently evaluating further development plans for AEZS-108, our targeted doxorubicin conjugate, after recent positive Stage 2 outcomes in endometrial and ovarian cancer. In endocrinology, we are in the process of reactivating a Stage 3 trial with this oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormones deficiency.’ SOURCE AETERNA ZENTARIS INC.

Aflac releases eighth new television commercial of 2009 Aflac today unveiled its eighth new television business of 2009, titled Soccer.Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, ‘The termination of our contract with sanofi-aventis U.S. Was expected in light of last week’s announcement. Our clinical development efforts will now be centered on the following late-stage substances: in oncology, Keryx, our licensee and partner in North America, has initiated a Stage 3 trial in multiple myeloma with perifosine just, our oral PI3K/Akt inhibitor compound. We are also currently evaluating further development plans for AEZS-108, our targeted doxorubicin conjugate, after recent positive Stage 2 outcomes in endometrial and ovarian cancer. In endocrinology, we are in the process of reactivating a Stage 3 trial with this oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormones deficiency.’ SOURCE AETERNA ZENTARIS INC.

Aflac releases eighth new television commercial of 2009 Aflac today unveiled its eighth new television business of 2009, titled Soccer.